| Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children (NCT05124067) | Tanta University | 2021-10-27 |
| SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors (NCT05354843) | Etern BioPharma (Shanghai) Co., Ltd | 2021-10-27 |
| A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (NCT05091346) | Eisai Inc. | 2021-10-27 |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (NCT07280377) | Oncolytics Biotech | 2021-10-27 |
| Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (NCT04989803) | Kite, A Gilead Company | 2021-10-27 |
| A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers (NCT05102266) | Boryung Pharmaceutical Co., Ltd | 2021-10-27 |
| A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects (NCT05137548) | Antios Therapeutics, Inc | 2021-10-27 |
| A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers (NCT06246695) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-10-27 |
| A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (NCT05103241) | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 2021-10-26 |
| A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months (NCT05212623) | Jiangsu Province Centers for Disease Control and Prevention | 2021-10-26 |
| A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. (NCT07392736) | Advenchen Laboratories, LLC | 2021-10-26 |
| A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer (NCT04993430) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-10-26 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State (NCT05098275) | Dong-A ST Co., Ltd. | 2021-10-26 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 (NCT05082779) | Cascade Pharmaceuticals, Inc | 2021-10-26 |
| Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study (NCT05086523) | BackBeat Medical Inc | 2021-10-25 |
| A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer (NCT05103826) | Jiangsu HengRui Medicine Co., Ltd. | 2021-10-25 |
| A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies (NCT05048134) | Jiangsu HengRui Medicine Co., Ltd. | 2021-10-25 |
| A Study of QLS31905 in Patients With Advanced Solid Tumors (NCT05278832) | Qilu Pharmaceutical Co., Ltd. | 2021-10-25 |
| A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein (NCT05075772) | Boehringer Ingelheim | 2021-10-25 |
| First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) (NCT05099172) | Bayer | 2021-10-25 |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (NCT04957290) | Noxopharm Limited | 2021-10-25 |
| Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis (NCT05114889) | Biosion, Inc. | 2021-10-25 |
| Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106907) | Fundamenta Therapeutics, Ltd. | 2021-10-25 |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission (NCT05010772) | M.D. Anderson Cancer Center | 2021-10-25 |
| Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients (NCT05033925) | Gadjah Mada University | 2021-10-25 |
| Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma (NCT05106946) | Fundamenta Therapeutics, Ltd. | 2021-10-25 |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors (NCT04337177) | Valent Technologies, LLC | 2021-10-25 |
| Safety, Tolerability, and Pharmacokinetics of IXT-m200 (NCT05027451) | InterveXion Therapeutics, LLC | 2021-10-25 |
| A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants (NCT05062200) | Janssen Pharmaceutical K.K. | 2021-10-25 |
| Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis (NCT05258331) | GC Cell Corporation | 2021-10-25 |
| STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS (NCT05093205) | Pfizer | 2021-10-25 |
| Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan (NCT05025956) | Steadman Philippon Research Institute | 2021-10-24 |
| A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors (NCT04991740) | Janssen Research & Development, LLC | 2021-10-24 |
| PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion (NCT05343715) | Bio Sidus SA | 2021-10-23 |
| Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration (NCT06547242) | Berlin-Chemie AG Menarini Group | 2021-10-22 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) (NCT05168904) | Cyclacel Pharmaceuticals, Inc. | 2021-10-22 |
| Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali (NCT05135273) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-22 |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (NCT04929223) | Hoffmann-La Roche | 2021-10-22 |
| A Target Occupancy Study With Ritlecitinib. (NCT05128058) | Pfizer | 2021-10-22 |
| Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers (NCT04873063) | SOFAR S.p.A. | 2021-10-22 |
| Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation (NCT04804891) | Columbia University | 2021-10-22 |
| A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016A" With "BR1016B" in Healthy Volunteers (NCT05102903) | Boryung Pharmaceutical Co., Ltd | 2021-10-22 |
| A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus (NCT05067270) | Eli Lilly and Company | 2021-10-22 |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies (NCT05028478) | Curon Biopharmaceutical (Australia) Co Pty Ltd | 2021-10-22 |
| Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma (NCT04975152) | H. Lee Moffitt Cancer Center and Research Institute | 2021-10-22 |
| A Study of FDA018-ADC in Patients With Advanced Solid Tumors (NCT05174637) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 2021-10-22 |
| Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer (NCT05052099) | University Hospital, Essen | 2021-10-22 |
| To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI (NCT05148403) | Beijing Tiantan Hospital | 2021-10-22 |
| Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients (NCT04634435) | Biohaven Pharmaceuticals, Inc. | 2021-10-21 |
| Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors (NCT06940349) | Rabin Medical Center | 2021-10-21 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome (NCT04652960) | National Cancer Institute (NCI) | 2021-10-21 |
| Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (NCT04146298) | Changhai Hospital | 2021-10-21 |
| CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma (NCT05052567) | Qilu Pharmaceutical Co., Ltd. | 2021-10-21 |
| A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors (NCT04857372) | Novartis Pharmaceuticals | 2021-10-21 |
| A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma (NCT05127811) | Zentera Therapeutics HK Limited | 2021-10-21 |
| EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers (NCT05176665) | Shanghai EpimAb Biotherapeutics Co., Ltd. | 2021-10-21 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707 (NCT05068466) | Incyte Biosciences Japan GK | 2021-10-21 |
| Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (NCT04316169) | Medical College of Wisconsin | 2021-10-21 |
| Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） (NCT05119972) | Guangdong Raynovent Biotech Co., Ltd | 2021-10-21 |
| Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease (NCT05045482) | Zydus Therapeutics Inc. | 2021-10-21 |
| A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants (NCT05067439) | Pfizer | 2021-10-21 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects (NCT05045313) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-20 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497) | National Cancer Institute (NCI) | 2021-10-20 |
| Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (NCT05101096) | Gilead Sciences | 2021-10-20 |
| Study of DTRI-031 in Healthy Volunteers (NCT05005520) | Basking Biosciences, Inc. | 2021-10-20 |
| A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors (NCT04914286) | Genfleet Therapeutics (Shanghai) Inc. | 2021-10-20 |
| A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries (NCT05000983) | University of Manitoba | 2021-10-20 |
| A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma (NCT05115292) | BJ Bioscience, Inc. | 2021-10-20 |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (NCT04486352) | Alliance Foundation Trials, LLC. | 2021-10-20 |
| A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT05091541) | Nanjing IASO Biotechnology Co., Ltd. | 2021-10-20 |
| Isothiocyanates and Metabolic Health (NCT05070585) | The Swedish School of Sport and Health Sciences | 2021-10-20 |
| A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants (NCT05154136) | Arcus Biosciences, Inc. | 2021-10-20 |
| Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (NCT04697576) | Carlo Contreras | 2021-10-20 |
| Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM (NCT05052970) | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2021-10-20 |
| CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (NCT05121038) | Anup Kasi | 2021-10-20 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537) | Pfizer | 2021-10-20 |
| A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants (NCT05096598) | Zealand Pharma | 2021-10-19 |
| Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (NCT04847063) | National Cancer Institute (NCI) | 2021-10-19 |
| T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients (NCT05141058) | Children's National Research Institute | 2021-10-19 |
| Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED) (NCT05101122) | Apnimed | 2021-10-19 |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (NCT05083481) | Astellas Pharma Global Development, Inc. | 2021-10-19 |
| A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (NCT05150405) | Qilu Pharmaceutical Co., Ltd. | 2021-10-19 |
| Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers (NCT04781322) | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 2021-10-19 |
| Identification of a Safe and Non-Psychedelic Dose of Psilocybin (NCT07710027) | Diamond Therapeutics Inc. | 2021-10-19 |
| A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood (NCT05076409) | Boehringer Ingelheim | 2021-10-19 |
| Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure (NCT03998735) | Masonic Cancer Center, University of Minnesota | 2021-10-19 |
| Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds (NCT05710094) | SoftOx Solutions AS | 2021-10-19 |
| Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty (NCT04919135) | Vinmec Research Institute of Stem Cell and Gene Technology | 2021-10-19 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19 (NCT05065645) | Apeiron Biologics | 2021-10-19 |
| Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III) (NCT04990388) | Ultragenyx Pharmaceutical Inc | 2021-10-18 |
| Use of a GLP-1R Agonist to Treat Opioid Use Disorder (NCT04199728) | Milton S. Hershey Medical Center | 2021-10-18 |
| CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (NCT05081492) | City of Hope Medical Center | 2021-10-18 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis (NCT04985812) | Janssen Research & Development, LLC | 2021-10-18 |
| Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT05641558) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2021-10-18 |
| A Study of HG381 Administered to Patients With Advanced Solid Tumors (NCT04998422) | HitGen Inc. | 2021-10-18 |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies (NCT05123482) | AstraZeneca | 2021-10-18 |
| A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer (NCT04958239) | Boehringer Ingelheim | 2021-10-18 |
| Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers (NCT05556863) | Electra Therapeutics Inc. | 2021-10-18 |